Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 20/100

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: Bernstein Liebhard LLP has filed a securities class action lawsuit against Alto Neuroscience, Inc. on behalf of investors who acquired shares in the company. The lawsuit alleges that the defendants made misrepresentations regarding ALTO-100, a drug for major depressive disorder. This legal action follows significant losses experienced by investors since the company's IPO on February 2, 2024. Those impacted can file to serve as lead plaintiffs, with action required by September 19, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Alto Neuroscience for misrepresentations about the clinical prospects of its drug ALTO-100.
  • Investors are facing large losses following the company's initial public offering.
  • The lawsuit includes specific allegations concerning the credibility of the company's statements during the IPO.

Full Press Release Details

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired: (a) Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”).
For more information, submit a form at Alto Neuroscience, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Defendants made misrepresentations concerning the clinical, regulatory, and commercial prospects of ALTO-100, a drug developed for the treatment of patients with major depressive disorder.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 19, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

alto neuroscience lawsuit
alto neuroscience class action

Frequently Asked Questions

What is the Alto Neuroscience class action lawsuit about?

The lawsuit involves misrepresentations regarding ALTO-100's prospects for treating major depressive disorder.

Who can participate in the class action?

Investors who bought Alto securities between February 2, 2024, and October 22, 2024, can participate.

When is the deadline to file as lead plaintiff?

The deadline to file papers to serve as lead plaintiff is September 19, 2025.

Are there any fees to join the class action?

No, all representation is on a contingency fee basis, with no fees for shareholders.

How can I get more information about the lawsuit?

You can contact Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

Last updated: Jul 22, 2025